Compare Ginkgo Bioworks Holdings Inc (DNA) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs ING Groep NV — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.09 (market cap $763.64M), while ING Groep NV trades at $33.38 (market cap $93.76B). The key difference: ING Groep NV is far larger — about 122.8× Ginkgo Bioworks Holdings Inc's market cap, and ING Groep NV pays a 3.95% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and ING Groep NV for 94 Days on average.
| DNA | ING | |
|---|---|---|
Market Cap | $763.64M | $93.76B |
Volume | 3,204,177 | 4,620,220 |
Sector | Health | Financials |
52-Week High | $15.83 | $37.27 |
52-Week Low | $5.48 | $23.66 |
Typical Hold Time | 7 Days | 94 Days |
Enterprise Value | $865.59M | $236.48B |
Dividend Yield | — | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
ING stock trades at $33.28, down 1.89% today, with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, maintains a 28.34% net income margin, and analysts show strong support with 11 buy ratings versus no sell ratings. Recent news highlights management's raised ROE target above 16% for 2027 and strategic focus on organic growth.
The investment case balances solid profitability and analyst optimism against technical weakness and cash flow challenges. Upside potential exists from earnings momentum and strategic initiatives, while risks include persistent negative operating cash flows and regulatory scrutiny in international markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
